Deutsche Bank’s Avidity Biosciences RNAM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
Sell
-166,841
Closed -$12M 3714
2025
Q4
$12M Sell
166,841
-97,773
-37% -$6.32M ﹤0.01% 1024
2025
Q3
$11.5M Buy
264,614
+23,611
+10% +$954K ﹤0.01% 1011
2025
Q2
$6.84M Buy
241,003
+56,388
+31% +$1.68M ﹤0.01% 1115
2025
Q1
$5.45M Sell
184,615
-8,971
-5% -$279K ﹤0.01% 1216
2024
Q4
$5.63M Buy
193,586
+30,340
+19% +$1.27M ﹤0.01% 1280
2024
Q3
$7.5M Buy
163,246
+16,676
+11% +$724K ﹤0.01% 1118
2024
Q2
$5.99M Buy
146,570
+11,821
+9% +$339K ﹤0.01% 1176
2024
Q1
$3.44M Sell
134,749
-628,100
-82% -$9.84M ﹤0.01% 1420
2023
Q4
$6.9M Buy
762,849
+628,299
+467% +$4.2M ﹤0.01% 1129
2023
Q3
$858K Buy
134,550
+4,748
+4% +$40.9K ﹤0.01% 1826
2023
Q2
$1.44M Sell
129,802
-35,203
-21% -$442K ﹤0.01% 1786
2023
Q1
$2.53M Buy
165,005
+13,077
+9% +$288K ﹤0.01% 1560
2022
Q4
$3.37M Buy
151,928
+10,678
+8% +$159K ﹤0.01% 1386
2022
Q3
$2.31M Buy
141,250
+16,292
+13% +$312K ﹤0.01% 1555
2022
Q2
$1.82M Buy
124,958
+2,442
+2% +$36.3K ﹤0.01% 1821
2022
Q1
$2.26M Sell
122,516
-2,422
-2% -$41.1K ﹤0.01% 1811
2021
Q4
$2.97M Sell
124,938
-220,372
-64% -$5.26M ﹤0.01% 1751
2021
Q3
$8.51M Buy
345,310
+3,686
+1% +$80.1K ﹤0.01% 1227
2021
Q2
$8.44M Sell
341,624
-132
-0% -$3.07K ﹤0.01% 1258
2021
Q1
$7.45M Buy
341,756
+229,472
+204% +$5.62M ﹤0.01% 1345
2020
Q4
$2.87M Buy
112,284
+3,348
+3% +$97.6K ﹤0.01% 1677
2020
Q3
$3.07M Buy
108,936
+8,936
+9% +$258K ﹤0.01% 1491
2020
Q2
$2.83M Buy
+100,000
New +$2.88M ﹤0.01% 1597

Other funds holding RNAM

Deutsche Bank's RNAM Position: Q1 2026 in Review

Deutsche Bank sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 166,841 shares — an estimated $12M sold.

Deutsche Bank first reported a position in RNAM in Q2 2020 and held it in 23 quarters. The position peaked at $12M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.

  • Deutsche Bank reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
  • Deutsche Bank sold 166,841 Avidity Biosciences shares in Q1 2026, an estimated $12M.
  • Deutsche Bank first reported a position in Avidity Biosciences in Q2 2020 and held it in 23 quarters.
  • Deutsche Bank's Avidity Biosciences position peaked at $12M in Q4 2025.
  • 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.

Based on Deutsche Bank's 13F filing for Q1 2026, filed 6 May 2026.